For the second quarter of FY 2023, DENALI THERAPEUTICS ($NASDAQ:DNLI) reported a total revenue of USD 294.1 million, representing a dramatically increased figure from the USD 52.5 million reported in the corresponding quarter of FY 2022. The company also saw a remarkable turnaround in net income, from a negative USD 58.8 million to USD 183.4 million.
DENALI’s stock opened at $26.0 and closed at $25.8, representing a 1.0% decrease from the last closing price of 26.1. Despite the slight dip in stock prices, DENALI was still able to report a positive quarter due to strong sales of its innovative treatments. The company boasted increased sales of its neurological and musculoskeletal products, including a new drug for Huntington’s Disease that has seen particularly high demand. Analysts have applauded DENALI for its strong performance this quarter, and the company is optimistic about the future.
DENALI is actively developing new treatments for various diseases and conditions, and is confident that their continued success will bring more investor attention and propel the stock prices higher in the coming months. With their focus on healthcare innovation, DENALI THERAPEUTICS is poised to be a leader in the industry for many years to come. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Denali Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Denali Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Denali Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Denali Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Denali Therapeutics Stock Fair Value Calculation
At GoodWhale, we specialize in analyzing the fundamentals of companies to estimate their intrinsic value. In this case, we have taken a comprehensive look at DENALI THERAPEUTICS and come up with an estimated intrinsic value of $99.7 per share. This calculation is based on our proprietary Valuation Line. Currently, DENALI THERAPEUTICS shares are trading at $25.8, which means they are undervalued by 74.1%. This presents an interesting opportunity for investors who are looking to buy undervalued stocks. With the right timing, investors may be able to capitalise on this discrepancy between the intrinsic value and stock price and benefit from future appreciation in the stock price. More…
Risk Rating Analysis
Star Chart Analysis
The biotech sector is full of companies vying for market share andDenali Therapeutics Inc is no different. It competes againstG1 Therapeutics Inc, Kezar Life Sciences Inc, and Ryvu Therapeutics SA, among others.
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in Phase III clinical trials for the treatment of small cell lung cancer. G1 Therapeutics Inc has a market cap of 486.46M as of 2022 and a Return on Equity of -117.43%.
– Kezar Life Sciences Inc ($NASDAQ:KZR)
Kezar Life Sciences Inc is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of novel small molecule therapeutics to treat autoimmune and other inflammatory diseases. The company has a market cap of 506.62M as of 2022 and a Return on Equity of -14.21%. Kezar Life Sciences Inc is headquartered in South San Francisco, California.
– Ryvu Therapeutics SA ($LTS:0RKT)
Ryu Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of serious and life-threatening diseases. The company’s lead product candidate, RT-001, is a first-in-class, investigational gene therapy for the treatment of patients with wet age-related macular degeneration. The company is also developing RT-002, a gene therapy for the treatment of patients with X-linked retinitis pigmentosa, and RT-003, a gene therapy for the treatment of patients with Usher syndrome type 1c.
Investors should pay close attention to DENALI THERAPEUTICS as it reported strong second quarter earnings for FY2023. This indicates that DENALI THERAPEUTICS is in a strong financial position and should be considered a viable investment opportunity. Further research into the company’s financials and products should be conducted in order to make a more informed decision regarding investing in DENALI THERAPEUTICS.